HeartFlow, Inc. (HTFL)
| Market Cap | 2.61B |
| Revenue (ttm) | 176.03M +39.9% |
| Net Income | -116.79M |
| EPS | -3.17 |
| Shares Out | 85.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 699,450 |
| Open | 31.40 |
| Previous Close | 31.24 |
| Day's Range | 30.11 - 31.69 |
| 52-Week Range | 20.13 - 41.22 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 38.20 (+25.49%) |
| Earnings Date | May 14, 2026 |
About HTFL
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart’s arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heart... [Read more]
Financial Performance
In 2025, HeartFlow's revenue was $176.03 million, an increase of 39.92% compared to the previous year's $125.81 million. Losses were -$116.79 million, 21.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for HTFL stock is "Strong Buy." The 12-month stock price target is $38.2, which is an increase of 25.49% from the latest price.
News
Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026
SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial r...
Heartflow Files Patent Infringement Lawsuit Against Cleerly
Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform Heartflow asserts that Cleerly infringed foundational patented technology central to the Hea...
HeartFlow Earnings Call Transcript: Q4 2025
Q4 revenue grew over 40% year-over-year, driven by strong FFRct and Plaque Analysis adoption, with 2026 guidance set for 24–26% growth and gross margin expansion. Plaque revenue and account growth are...
Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning
Three presentations at ACC reinforce Heartflow's AI-powered technology predicts MACE, drives superior lipid outcomes and results in cost-effective care First patient enrolled in p ioneering N AVIGAT...
HeartFlow Transcript: Morgan Stanley Technology, Media & Telecom Conference 2026
AI-powered platform for coronary artery disease diagnosis is expanding rapidly, leveraging a proprietary, FDA-cleared, and reimbursed technology suite. Key growth drivers include Plaque Analysis, new ...
Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference
MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of mana...
Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release fina...
HeartFlow Transcript: 44th Annual J.P. Morgan Healthcare Conference
AI-powered coronary artery disease solutions achieved record account growth and strong financial results in 2025, with Plaque Analysis poised to drive further expansion in 2026. The company targets pr...
Heartflow Plaque Analysis Now Covered by Aetna Insurance Plans Nationwide and for the Majority of Insured Lives in the U.S.
MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Ana...
Heartflow to Participate in the 44th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today anno...
Heartflow Plaque Analysis Now Supported by Scientific Statements From American College of Cardiology and American Heart Association for Personalized Management of Patients with Suspected CAD
Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment
Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease
Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health Service...
HeartFlow Transcript: Piper Sandler 37th Annual Healthcare Conference
AI-powered coronary disease diagnostics platform is expanding rapidly, with strong clinical validation, a growing installed base, and a robust sales force. Plaque Analysis is set to broaden the addres...
Heartflow to Participate in the Piper Sandler 37th Annual Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today anno...
HeartFlow Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 41% year-over-year to $46.3M, driven by strong AI platform adoption and a rapidly expanding installed base. Gross margin improved, losses narrowed, and the company is well-capital...
Heartflow Reports Third Quarter 2025 Financial Results
MOUNTAIN VIEW, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today repo...
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification
NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FI...
Heartflow to Present Late-Breaking Data Advancing AI-Driven Heartflow Plaque Analysis at AHA 2025
MOUNTAIN VIEW, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new ...
Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release fina...
New Heartflow PCI Navigator to Equip Interventional Cardiologists with Pre-procedural Insights to Enable PCI Planning
PLAN CALCIUM study to be presented at TCT 2025 conference highlights how AI-powered plaque analysis can inform lesion preparation and calcium modification planning NAVIGATE-PCI registry to enroll appr...
Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform
AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide
HeartFlow Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
AI-driven coronary artery disease diagnostics are seeing rapid adoption, with strong Q2 growth and expanding gross margins. New Plaque Analysis technology is poised to drive the next wave of growth, w...
Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of mana...
Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its ups...
Heartflow Stock Opens Nearly 50% Above IPO Price in Latest Hot Debut
Medical imaging company Heartflow rose nearly 50% on its first day, joining Firefly, Figma, and Circle as big IPO gainers.